Latest Information Update: 16 Jul 2016
At a glance
- Originator Centocor
- Class Antianaemics
- Mechanism of Action Erythropoietin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Anaemia in USA
- 17 Jan 2006 Phase-I clinical trials in Anaemia in USA (unspecified route)